To evaluate a potential benefit that EGFR ligands produced by tumor cells might provide to modified T cells for tumor recognition, we examined the capacity of EGFR-transduced OT-1 CD8+ T cells to recognize and lyse tumor cells expressing ovalbumin. The gene discussed is CD8A; the disease is neoplasm.